In Study 22, the tremelimumab/Imfinzi regimen achieved a median overall survival (OS) of 18.7 months, a finding which AZ’s head of oncology R&D José Baselga said could “change the treatment ...

AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results. The drugmaker said ...

23 December 2024 As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab with tremelimumab for treating limited-stage ...